IP Library Granted Patent US 8,980,295
Granted Patent B2
US 8,980,295 · App. 13/411,387 · Granted Mar 17, 2015

Multifunctional in situ polymerized network via thiol-ene and thiol-maleimide chemistry

Inventors: Weiyuan J. Kao (Middleton, WI); Yao Fu (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C08J3/246A61L15/26A61L15/44A61L15/585A61L27/18A61L27/26A61L27/52A61L27/54C08H1/06C08L1/04C08L1/286C08L5/04C08L5/08C08L89/00A61K38/00C08J2371/02C08J2389/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,295
App. No.
13/411,387
Granted
Mar 17, 2015
Kind
B2
Abstract

Biomaterials that support cell attachment and growth are provided. In one aspect, biomaterials are provided comprising a first polymer matrix comprising reactive amino moieties and a second polymer matrix that interpenetrates with the first polymer matrix, where the second polymer matrix comprises a poly(alkylene oxide) comprising two or more alkylene oxide oligomers joined by gamma-thioether carbonyl linkages. In another aspect, biomaterials are provided comprising at least one biopolymer comprising amino groups, thiol groups, and bifunctional modifiers connecting at least some of the amino groups to at least some of the thiol groups; and at least one poly(alkylene oxide) cross-linked to at least two thiol groups of the biopolymer. The biomaterials may further comprise a pharmacologically active agent or cells. Methods of administering such biomaterials to a patient in need thereof are also provided.

Claims (38)

1. A biomaterial comprising:

at least one biopolymer comprising

naturally occurring amino groups and

at least two bifunctional modifiers wherein each bifunctional modifier has the formula:

-A-[(CR 1 R 2 ) m —O] n —Z

A is a divalent moiety covalently bonded to the naturally occurring amino group of the biopolymer and Z is a monovalent moiety comprising a thiol group;

at least one poly(alkylene oxide) cross-linked to at least two of the thiol groups of the biopolymer;

wherein;

the divalent moiety is selected from the group consisting of —O—, —S—, C 1-24 -alkyl, C 2-24 -alkenyl, C 2-24 -alkynyl, C 1-24 -alkoxy, C 1-24 -heteroalkyl, C 2-24 -heteroalkenyl, C 2-24 -heteroalkynyl, cyano-C 1-24 -alkyl, C 3-10 -cycloalkyl, C 3-10 -cycloalkenyl, C 3-10 -cycloheteroalkyl, C 3-10 -cycloheteroalkenyl, acyl, acyl-C 1-24 -alkyl, acyl-C 2-24 -alkenyl, acyl-C 2-24 -alkynyl, carboxy, C 1-24 -alkylcarboxy, C 2-24 -alkenylcarboxy, C 2-24 -alkynylcarboxy, carboxy-C 1-24 -alkyl, carboxy-C 2-24 -alkenyl, carboxy-C 2-24 -alkynyl, aryl, aryl-C 1-24 -alkyl, aryl-C 2-24 -alkenyl, aryl-C 2-24 -alkynyl, heteroaryl, heteroaryl-C 1-24 -alkyl, heteroaryl-C 2-24 -alkenyl, heteroaryl-C 2-24 -alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate;

at each occurrence R 1 and R 2 is independently selected from the group consisting of H, methyl, and ethyl;

m is an integer from 2 to 8; and

n is an integer ranging from 1 to 20,000.

2. The biomaterial of claim 1 wherein the biopolymer comprises gelatin, collagen, whey protein, chitosan, or combinations of any two or more thereof.

3. The biomaterial of claim 1 wherein the biopolymer comprises gelatin and/or collagen.

4. The biomaterial of claim 1 wherein the biopolymer comprises Type A gelatin, Type B gelatin or both.

5. The biomaterial of claim 1 wherein the monovalent moiety is selected from the group consisting of thiol, cysteine, carbonyl cysteine, homocysteine, cysteamine, cystamine, C 1-24 -alkylthiol, C 2-24 -alkenylthiol, C 2-24 -alkynylthiol, —O—C 1-24 -alkylthiol, C 1-24 -heteroalkylthiol, C 2-24 -heteroalkenylthiol, C 2-24 -heteroalkynylthiol, C 3-10 -cycloalkylthiol, C 3-10 -cycloalkenylthiol, C 3-10 -cycloheteroalkylthiol, C 3-10 -cycloheteroalkenylthiol, —C(O)—C 1-24 -alkylthiol, —C(O)—C 2-24 -alkenylthiol, —C(O)—C 2-24 -alkynylthiol, —OC(O)—C 1-24 -alkylthiol, —OC(O)—C 2-24 -alkenylthiol, —OC(O)—C 2-24 -alkynylthiol, arylthiol, C 1-24 -alkyl-arylthiol, C 2-24 -alkenyl-arylthiol, C 2-24 -alkynyl-arylthiol, heteroarylthiol, C 1-24 -alkyl-heteroarylthiol, C 2-24 -alkenyl-heteroarylthiol, and C 2-24 -alkynyl-heteroarylthiol.

6. The biomaterial of claim 1 wherein n is an integer from 1 to 2,000.

7. The biomaterial of claim 1 wherein n is an integer from 1 to 200.

8. The biomaterial of claim 1 wherein n is an integer from 1 to 100.

9. The biomaterial of claim 1 wherein the poly(alkylene oxide) is selected from the group consisting of poly(ethylene glycol), polypropylene glycol), and mixtures thereof.

10. The biomaterial of claim 9 wherein the biopolymer comprises gelatin, poly(ethylene glycol) and cysteine.

11. The biomaterial of claim 1 , further comprising a pharmacologically active agent entrained within the biomaterial or covalently attached to the biopolymer.

12. The biomaterial of claim 11 wherein the pharmacologically active agent is selected from the group consisting of vulnerary agents, hemostatic agents, antibiotics, antithelmintics, anti-fungal agents, hormones, anti-inflammatory agents, proteins, polypeptides, oligonucleotides, cytokines, and enzymes.

13. A method comprising administering a biomaterial of claim 11 to a patient in need of said pharmacologically active agent.

14. The biomaterial of claim 1 , further comprising living cells entrained within the biomaterial.

15. A method comprising administering a biomaterial of claim 14 to a patient in need of said living cells.

16. The method of claim 15 wherein the biomaterial comprises at least two layers, each layer comprising a different cell type.

17. A method comprising reacting a poly(alkylene oxide)-diacrylate with at least one biopolymer comprising naturally occurring amino groups and at least two bifunctional modifiers wherein each bifunctional modifier is of the formula

-A-[(CR 1 R 2 ) m —O] n —Z

A is a divalent moiety covalently bonded to the naturally occurring amino groups of the biopolymer and Z is a monovalent moiety comprising a thiol group, to provide a biomaterial in which the at least one poly(alkylene oxide) is cross-linked to at least two of the thiol groups of the biopolymer;

wherein

the divalent moiety is selected from the group consisting of —O—, —S—, C 1-24 -alkyl, C 2-24 -alkenyl, C 2-24 -alkynyl, C 1-24 -alkoxy, C 1-24 -heteroalkyl, C 2-24 -heteroalkenyl, C 2-24 -heteroalkynyl, cyano-C 1-24 -alkyl, C 3-10 -cycloalkyl, C 3-10 -cycloalkenyl, C 3-10 -cycloheteroalkyl, C 3-10 -cycloheteroalkenyl, acyl, acyl-C 1-24 -alkyl, acyl-C 2-24 -alkenyl, acyl-C 2-24 -alkynyl, carboxy, C 1-24 -alkylcarboxy, C 2-24 -alkenylcarboxy, C 2-24 -alkynylcarboxy, carboxy-C 1-24 -alkyl, carboxy-C 2-24 -alkenyl, carboxy-C 2-24 -alkynyl, aryl, aryl-C 1-24 -alkyl, aryl-C 2-24 -alkenyl, aryl-C 2-24 -alkynyl, heteroaryl, heteroaryl-C 1-24 -alkyl, heteroaryl-C 2-24 -alkenyl, heteroaryl-C 2-24 -alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate;

at each occurrence R 1 and R 2 is independently selected from the group consisting of H, methyl, and ethyl;

m is an integer from 2 to 8;

n is an integer ranging from 1 to 20,000.

18. The method of claim 17 , further comprising crosslinking the biopolymer and the poly(alkylene oxide) by photopolymerization or Michael addition.

19. The biomaterial of claim 1 , wherein the monovalent moiety is

20. The biomaterial of claim 2 , wherein the biomaterial further comprises calcium alginate, calcium/sodium alginate, oxidized regenerated cellulose, carboxymethylcellulose, amino-modified cellulose, or combinations of any two or more thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2012
From: KAO, WEIYUAN JOHN; FU, YAO
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 028064/0678 →
CONFIRMATORY LICENSE Recorded Mar 9, 2012
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027839/0266 →
Continuity (2)
Provisional Application 61448543 · Mar 2, 2011
Related Publication 20120225101A1 · Sep 6, 2012